Reinartz S - Search Results

1

Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.

Vyas M, Reinartz S, Hoffmann N, Reiners KS, Lieber S, Jansen JM, Wagner U, Müller R, von Strandmann EP. Vyas M, et al. Among authors: reinartz s. Oncoimmunology. 2017 Aug 21;6(9):e1339854. doi: 10.1080/2162402X.2017.1339854. eCollection 2017. Oncoimmunology. 2017. PMID: 28932639 Free PMC article.

2

Production of a single-chain fragment of the murine anti-idiotypic antibody ACA125 as phage-displayed and soluble antibody by recombinant phage antibody technique.

Schlebusch H, Reinartz S, Kaiser R, Grünn U, Wagner U. Schlebusch H, et al. Among authors: reinartz s. Hybridoma. 1997 Feb;16(1):47-52. doi: 10.1089/hyb.1997.16.47. Hybridoma. 1997. PMID: 9085128

3

Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report.

Reinartz S, Boerner H, Koehler S, Von Ruecker A, Schlebusch H, Wagner U. Reinartz S, et al. Hybridoma. 1999 Feb;18(1):41-5. doi: 10.1089/hyb.1999.18.41. Hybridoma. 1999. PMID: 10211787 Clinical Trial.

4

Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125.

Reinartz S, Wagner U, Giffels P, Gruenn U, Schlebusch H, Wallwiener D. Reinartz S, et al. Cancer Immunol Immunother. 2000 Jul;49(4-5):186-92. doi: 10.1007/s002620000126. Cancer Immunol Immunother. 2000. PMID: 10941901 Free PMC article.

5

Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.

Reinartz S, Hombach A, Köhler S, Schlebusch H, Wallwiener D, Abken H, Wagner U. Reinartz S, et al. Cancer Res. 2003 Jun 15;63(12):3234-40. Cancer Res. 2003. PMID: 12810653

6

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Möbus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U. Reinartz S, et al. Clin Cancer Res. 2004 Mar 1;10(5):1580-7. doi: 10.1158/1078-0432.ccr-03-0056. Clin Cancer Res. 2004. PMID: 15014007 Clinical Trial.

7

Current approaches in ovarian cancer vaccines.

Reinartz S, Wagner U. Reinartz S, et al. Minerva Ginecol. 2004 Dec;56(6):515-27. Minerva Ginecol. 2004. PMID: 15729204 Review.

8

Development of a delivery system for the continuous endogenous release of an anti-idiotypic antibody against ovarian carcinoma.

Hann E, Reinartz S, Clare SE, Passow S, Kissel T, Wagner U. Hann E, et al. Among authors: reinartz s. Hybridoma (Larchmt). 2005 Jun;24(3):133-40. doi: 10.1089/hyb.2005.24.133. Hybridoma (Larchmt). 2005. PMID: 15943560

9

Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.

Reinartz S, Pfisterer J, du Bois A, Jackisch C, Baumann KH, Wagner U. Reinartz S, et al. Hum Immunol. 2010 Jan;71(1):36-44. doi: 10.1016/j.humimm.2009.09.356. Hum Immunol. 2010. PMID: 19782714

10

Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.

Baumann KH, Klusmeier E, Eggemann I, Reinartz S, Almeroth A, Kalder M, Wagner U. Baumann KH, et al. Among authors: reinartz s. Breast Cancer (Auckl). 2009 Apr 7;3:23-34. doi: 10.4137/bcbcr.s2291. Breast Cancer (Auckl). 2009. PMID: 21556247 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters